Impact BioMedical, INC. Total Liabilities
Impact BioMedical, INC. (IBO) had Total Liabilities of $2.73 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-07
- 2026-06-30: Liabilities $2.73M.
- 2026-03-31: Liabilities $2.38M.
- 2025-12-31: Liabilities $1.85M.
- 2025-09-30: Liabilities $27.06M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $2.73M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $2.38M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.85M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $27.06M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $26.44M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $13.24M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $13.05M 10-K · filed 2026-03-11 |
| 2024-09-30 | $12.34M 10-Q · filed 2024-11-12 |
| 2023-12-31 | $16.37M 10-K · filed 2025-03-28 |
| 2023-09-30 | $15.50M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $15.29M 10-Q · filed 2023-10-05 |
| 2022-12-31 | $13.83M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |